focus -WSS

focus

author：leisure time 2025-10-01 18:43:52 - browse：513

Stock exchange — Drew Angerer/Getty Images

Viking Therapeutics said Tuesday that its closely watched oral obesity drug had succeeded in an early-stage trial and that it planned to advance the medicine into the next phase of development.

The top-line results released Tuesday were only from a Phase 1 study, which primarily focuses on a drug’s safety. But Viking said that in the study, its medicine led to a roughly 3.3% placebo-adjusted average weight loss after four weeks and that it showed no safety issues.

In preview notes, analysts had said that investors would want to see between 3% and 4% placebo-adjusted weight loss. Shares of San Diego-based Viking were up more than 20% in pre-market trading Tuesday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Bird flu outbreak in cows is latest avian flu curveball

hotspot

WSS

Extreme heat events are a public health emergency

Abortion clinic in Cancun will cater to Americans

BIO: Crackdown on China pharma industry would threaten U.S. drug supply

H5N1 bird flu virus started spreading in cows in Texas in December

Element Biosciences CEO lays out genome sequencing strategy

A clever new way to fix Medicaid and graduate medical education

focus

focus

hotspot

BioMarin wins approval for gene therapy to treat hemophilia A

AstraZeneca CEO says participant had neurological symptoms, could be discharged today

Supreme Court strikes down use of affirmative action

White House calls on federal agencies to crack down on AI abuses

In Memoriam: Notable people who died in 2023

The Sacklers, horror, and ‘The Fall of the House of Usher’

Medicare proposal to cover medical devices draws a mixed reaction

Victims of gun violence feel impacts long after bullet wound

In age of alternative facts, a scholarly course on calling out crap

Abortion clinic in Cancun will cater to Americans

knowledge

Element Biosciences CEO lays out genome sequencing strategy

FDA approves potent Eli Lilly obesity drug, Zepbound

Don't let 'shelved assets' gather dust. Make them into new lifesaving drugs

Cancer researcher Catriona Jamieson is sending tumors into space

Cue Health's Covid

Excited delirium, Elijah McClain, and emergency physicians

leisure time

hotspot

leisure time

leisure time